Open AccessLP(a) as a marker for coronary heart disease risk
Author(s) -
Scanu A. M.
Publication year - 1991
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960141306
Subject(s) - medicine , lipoprotein(a) , lipoprotein , apolipoprotein b , atherosclerotic cardiovascular disease , coronary heart disease , glycoprotein , in vivo , family history , plasma lipoprotein , risk factor , familial hypercholesterolemia , cardiology , endocrinology , disease , cholesterol , biochemistry , genetics , biology
Lipoprotein(a) or Lp(a) represents a class of lipoprotein particles having lipid composition similar to low‐density lipoprotein (LDL) and a protein moiety, apoB100, covalently linked to apo(a), a glycoprotein with striking structural similarities to plasminogen. High plasma levels of Lp(a) are associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD) by mechanisms yet to be determined. From in vitro and ex vivo observations it is apparent that because of its structural properties, Lp(a) can have both atherogenic and thrombogenic potentials. Means for correcting the high plasma levels of Lp(a) are still limited in effectiveness. The emerging notion that the pathogenicity of Lp(a) is increased in the presence of other risk factors, invites development of approaches for their correction, particularly in subjects with personal arid/or family history of ASCVD.